1. Home
  2. NUVL vs ZWS Comparison

NUVL vs ZWS Comparison

Compare NUVL & ZWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.50

Market Cap

9.8B

Sector

Health Care

ML Signal

HOLD

Logo Zurn Elkay Water Solutions Corporation

ZWS

Zurn Elkay Water Solutions Corporation

HOLD

Current Price

$50.81

Market Cap

7.9B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
ZWS
Founded
2017
1900
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
9.8B
7.9B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
NUVL
ZWS
Price
$123.50
$50.81
Analyst Decision
Strong Buy
Buy
Analyst Count
16
6
Target Price
$134.75
$53.67
AVG Volume (30 Days)
4.2M
833.0K
Earning Date
05-08-2026
04-21-2026
Dividend Yield
N/A
0.86%
EPS Growth
N/A
25.00
EPS
N/A
0.35
Revenue
N/A
$1,530,500,000.00
Revenue This Year
N/A
$6.90
Revenue Next Year
$1,239.49
$5.13
P/E Ratio
N/A
$146.54
Revenue Growth
N/A
19.40
52 Week Low
$71.14
$35.73
52 Week High
$123.69
$53.76

Technical Indicators

Market Signals
Indicator
NUVL
ZWS
Relative Strength Index (RSI) 66.42 58.31
Support Level $97.99 $49.72
Resistance Level $123.62 $51.18
Average True Range (ATR) 0.58 1.32
MACD 0.66 0.35
Stochastic Oscillator 99.45 75.45

Price Performance

Historical Comparison
NUVL
ZWS

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About ZWS Zurn Elkay Water Solutions Corporation

Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.

Share on Social Networks: